This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., To Board Of Directors

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the appointment of Douglas Williams, Ph.D., to its board of directors. Dr. Williams currently serves as executive vice president, research and development for Biogen Idec Inc. and was previously chief executive officer of ZymoGenetics, Inc.

“Ironwood is passionate about attracting board members who have business savvy, a strong interest in our company, absolute integrity, great strategic judgment and an owner-oriented mindset. We believe Doug possesses each of these critical characteristics and will be an excellent representative for Ironwood’s shareholders,” said Peter Hecht, chief executive officer of Ironwood. “Doug also has valuable perspective derived from his breadth of experience: he is a great drug hunter, as evidenced by his role in the discovery and development of blockbuster rheumatoid arthritis drug Enbrel, and he is also a terrific strategic thinker, as his successful leadership of ZymoGenetics and recent revitalization of Biogen’s research initiatives have demonstrated.”

“The Ironwood team has brought a pioneering product with a new mechanism of action to the gastrointestinal market, and they are developing a rich pipeline built on their commitment to innovation,” said Dr. Williams. “I look forward to collaborating with the team as they explore ways to maximize the appropriate utility of their approved product, advance their focused research and work to bring important new therapeutic options to patients for many years to come.”

Dr. Williams has served as executive vice president, research and development at Biogen Idec since January 2011. Previously, he held several senior executive positions, including chief executive officer and chief scientific officer, at ZymoGenetics, where he also served as a director. While at ZymoGenetics, he oversaw development of peginterferon lambda-1a, now in Phase III, and several other oncology and immunology programs. Before joining ZymoGenetics, Dr. Williams served as chief scientific officer and executive vice president of research and development at Seattle Genetics Inc., where he oversaw the development of cancer drug Adcetris ® (brentuximab vedotin). Before that he held a series of scientific and senior leadership positions over a decade at Immunex Corp., where he led development of blockbuster rheumatoid arthritis drug Enbrel ® (etanercept). Dr. Williams’ tenure at Immunex culminated with his position as executive vice president and chief technology officer, and he went on to serve as a senior vice president at Amgen Inc. following its acquisition of Immunex. Before joining industry, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, New York. He serves on the board of directors of Regulus Therapeutics Inc., and previously served on the board of directors of Oncothyreon Inc. and Array BioPharma Inc. Dr. Williams received his B.S. in Biological Sciences from the University of Massachusetts, Lowell and Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Memorial Institute Division.

About Ironwood Pharmaceuticals

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,106.70 +29.83 0.17%
S&P 500 2,000.02 +2.10 0.11%
NASDAQ 4,570.6370 +13.29 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs